Yahoo · Feb 26, 2026
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading
European equities traded in the US as American depositary receipts were sharply lower late Thursday
NASDAQ · CLLS
Healthcare · Biotechnology
$1.26
Up+$0.01 (+0.80%)
Updated Oct 10, 2026, 4:16 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CLLS
1M range · 0 trading sessions · Daily adjusted prices
CLLS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CLLS.
Company
Market Activity
Research & News
CLLS research
Company profile and research snapshot.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | ODDO BHF | Buy | — |
| Sep 14, 2026 | JEFFERIES | Buy | — |
| Aug 12, 2026 | CITIZENS | Outperform | — |
| Jul 8, 2026 | ODDO BHF | Buy | — |
| Jul 7, 2026 | ODDO BHF | Buy | — |
No generated briefing is available yet.
Yahoo · Feb 26, 2026
European equities traded in the US as American depositary receipts were sharply lower late Thursday
Yahoo · Feb 17, 2026
European equities traded in the US as American depositary receipts were marginally lower late Tuesda
Yahoo · Feb 10, 2026
European equities traded in the US as American depositary receipts were little changed late Tuesday
Yahoo · Feb 9, 2026
European equities traded in the US as American depositary receipts started the week modestly higher
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CLLS.